VC Playbook: Hubert Birner, managing partner for Montreal and Munich, is responsible for TVM Capital Life Science’s overall investment approach and global fund operations. At the November 2023 BIO-Europe conference, he sat down with In Vivo to discuss the VC’s strategy and expectations for the European life science sector in 2024.
TVM Capital Life Sciences is a transatlantic venture firm based in Munich, Germany. Hubert Birner, co-owner and managing partner at TVM, told In Vivo there was still a long way to go for the biotech sector in Europe compared to the US, but that “there's a lot of opportunity out there.”
TVM has a two-pronged strategy. First the firm is focused on early-stage companies, which are often one asset biotechs in...
Create an account to read this article
Already a subscriber?
The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
Jason Menzo, CEO of the Foundation Fighting Blindness, says the organization is adapting its funding strategy, navigating regulatory challenges and accelerating the translation of academic discoveries into industry-led clinical development.
Laura Lane, European head of Lilly Ventures, talked to In Vivo at the recent Bio-Europe meeting in a fireside chat about how strategic investments are shaping the future of biotech, Lilly's approach to early-stage innovation, and the evolving European investment landscape.
Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.
Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.
